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A B S T R A C T
Background
Published pharmaceutical industry–sponsored trials are more likely than non-industry-
sponsored trials to report results and conclusions that favor drug over placebo. Little is known
about potential biases in drug–drug comparisons. This study examined associations between
research funding source, study design characteristics aimed at reducing bias, and other factors
that potentially influence results and conclusions in randomized controlled trials (RCTs) of
statin–drug comparisons.
Methods and Findings
This is a cross-sectional study of 192 published RCTs comparing a statin drug to another
statin drug or non-statin drug. Data on concealment of allocation, selection bias, blinding,
sample size, disclosed funding source, financial ties of authors, results for primary outcomes,
and author conclusions were extracted by two coders (weighted kappa 0.80 to 0.97). Univariate
and multivariate logistic regression identified associations between independent variables and
favorable results and conclusions. Of the RCTs, 50% (95/192) were funded by industry, and 37%
(70/192) did not disclose any funding source. Looking at the totality of available evidence, we
found that almost all studies (98%, 189/192) used only surrogate outcome measures. Moreover,
study design weaknesses common to published statin–drug comparisons included inadequate
blinding, lack of concealment of allocation, poor follow-up, and lack of intention-to-treat
analyses. In multivariate analysis of the full sample, trials with adequate blinding were less likely
to report results favoring the test drug, and sample size was associated with favorable
conclusions when controlling for other factors. In multivariate analysis of industry-funded RCTs,
funding from the test drug company was associated with results (odds ratio ¼ 20.16 [95%
confidence interval 4.37–92.98], p , 0.001) and conclusions (odds ratio ¼ 34.55 [95%
confidence interval 7.09–168.4], p , 0.001) that favor the test drug when controlling for other
factors. Studies with adequate blinding were less likely to report statistically significant results
favoring the test drug.
Conclusions
RCTs of head-to-head comparisons of statins with other drugs are more likely to report
results and conclusions favoring the sponsor’s product compared to the comparator drug. This
bias in drug–drug comparison trials should be considered when making decisions regarding
drug choice.
The Editors’ Summary of this article follows the references.
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Introduction
Bias is the combination of various study design, data
analysis, and presentation factors that make the results differ
systematically from the truth [1]. Various factors can lead to
bias in randomized controlled trials (RCTs) of drug efficacy,
including framing of the research question, design and
conduct of the study, and analysis of the data [2,3]. Whether
the results are reported in full, or whether there is selective
reporting of outcomes can also contribute to biased results
and conclusions [4–7].
Most studies that have attempted to identify factors that
may be associated with bias have examined individual design
features, including randomization [8,9], concealment of
allocation [10], double blinding [9,10], sample size [11–14],
choice of drug comparator [15–18], and choice of statistical
analysis [19,20]. In this study, we examine the relative
contributions of different factors to favorable results and
conclusions.
One factor that has been associated with possible bias is
funding source for a study. Trials supported by pharmaceut-
ical companies are more likely than those with non-industry
sponsors to report results and conclusions that are favorable
towards the sponsor’s product compared to placebo
[14,15,21–28]. However, few studies examining the association
of funding source and outcome adjust for potential con-
founders, such as study design characteristics or type of
intervention. For example, study characteristics such as
randomization sequence generation, concealment of alloca-
tion, blinding, sample size, or choice of drug comparator
might also contribute to statistically significant results [28,29].
Although the association of pharmaceutical industry sponsor-
ship with results and conclusions that favor the sponsor’s
product over placebo is clear [22,23], the potential influence
of funding source when the funder manufactures one of two
competing drugs undergoing comparison has not been well
described. Although Heres et al. found that results of head-to-
head comparisons of second-generation antipsychotics have
contradictory conclusions depending on which company
sponsored the study, they did not analyze the potential
effects of other study design characteristics [30].
Statins are an interesting class of drug for investigating the
influence of funding source on outcomes of head-to-head
drug comparisons because a number of statins are manufac-
tured by competing companies. Statins are widely prescribed
as effective first-line agents for lowering cholesterol and
other lipids. At the time of this study, seven statin drugs were
marketed in the United States by competing companies,
although one of these drugs has since been withdrawn.
Alternative classes of drugs were also available to treat the
same condition. As strong evidence suggests that statins are
more effective than placebo in reducing lipids [31], drug–
drug comparison trials involving statins are the most relevant
for making policy decisions about choosing a statin. Choice of
a statin should depend on data from statin–statin compar-
isons of low-density lipoprotein reduction at comparable
doses, ability to achieve cholesterol-reduction goals, and
effects on a variety of other outcomes such as death, coronary
events, or stroke [32]. For example, formulary committees use
head-to-head drug comparisons to decide which of the statins
will be placed on their formulary. Therefore, it is important
to explore possible biases in statin–statin comparisons.
This cross-sectional study examines associations between
research funding source, study design characteristics aimed at
reducing bias, and other factors for which results and
conclusions have been published in RCTs of statin–drug
comparisons. We hypothesized that the results and conclu-
sions of trials are more likely to favor the statin made by the
sponsor of the study and that other design features, such as
concealment of allocation, blinding, and sample size are also
associated with statistically significant results that favor the
statin produced by the study’s sponsor.
Methods
Search Strategy
We electronically searched PubMed to identify reports of
RCTs published between January 1999 and May 2005. The
following MeSH terms or Substance Names of the seven
available statins were used: ‘‘simvastatin’’ OR ‘‘cerivastatin’’
OR ‘‘pravastatin’’ OR ‘‘atorvastatin’’ OR ‘‘fluvastatin’’ OR
‘‘rosuvastatin’’ OR ‘‘lovastatin’’. The search was limited to
‘‘randomized controlled trials’’ and ‘‘humans’’. We restricted
our search to these years because journals strengthened their
policies requiring disclosure of funding sources and financial
ties of authors during this period [33]. We also searched the
reference lists of all potentially relevant articles identified
through the PubMed search. Our search included articles
published in any language.
Inclusion and Exclusion Criteria
We reviewed abstracts of all citations and retrieved articles
based on the following inclusion criteria: (1) RCT; (2) statin
drug compared to a different statin drug or another, non-
statin, drug; (3) efficacy measured in humans; and (4) original
research, defined as studies that appeared to present original
data and did not specifically state that they were reviews.
Studies with the primary objective of assessing the effect of a
combination of a statin and another drug were included if
there was a comparison of the statin alone with the other
drug. If a placebo arm was also included in the trial, we
included only the data from the statin–drug comparison.
The following exclusion criteria were used to screen all
abstracts: (1) pharmacokinetic or pharmacodynamic studies,
since they do not involve testing of clinical efficacy outcomes;
(2) studies including only rationale and design elements,
editorials, letters to the editor, commentaries, abstracts,
unpublished reports, reviews; (3) studies comparing different
doses of one type of statin; (4) studies comparing statins to
placebo only; (5) studies comparing statins to a non-drug
intervention (e.g., diet, exercise); (6) studies in which the
statin was present in all the comparison groups; (7) absence of
statistical comparison or lack of sufficient data; and (8) in
vitro analyses. Any discrepancies about inclusion were
discussed by the authors of the present paper until consensus
was achieved. No identical publications were identified.
However, as we were interested in the published reports
from trials, we did include multiple publications from the
same study if the publications reported different outcomes.
Data Extraction
One investigator (F. Oostvogel), who was not blinded to
author names and affiliations, funding sources, and financial
disclosure, extracted all data from each article. A second
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coder (L. Bero), who was blinded to funding source and
financial tie information, independently extracted data on
concealment of allocation, selection bias, blinding, sample
size, results for primary outcomes, and author conclusions.
Inter-coder reliability was very good (weighted kappa 0.80 to
0.97). In cases of disagreement, the two coders discussed the
papers and reached agreement. We extracted data on the
following publication characteristics, which have been shown
to be independently related to favorable results or con-
clusions of drug studies [8–10,13,22,27,34,35].
Journal Characteristics
Peer-review status. Each article was classified as peer
reviewed, non-peer reviewed, or unknown, based on infor-
mation found on the website of the journal where the article
was published. A publication was considered peer reviewed if
the website mentioned that the journal had a peer-review
process or if it was stated that the manuscripts were evaluated
by at least one external expert in the field; otherwise, a
publication was considered non-peer reviewed. Peer-review
status was classified as unknown if we could find no
information on the journal.
Impact factor. Impact factor was obtained from the
Institute for Scientific Information, 2004 data [36].
Author Characteristics
Institutional affiliation. The institutional affiliation of the
corresponding author was obtained from the article and
classified into (1) academic/university, (2) government, (3)
private nonprofit, (4) industry, (5) hospital, (6) other, or (7)
unable to determine.
Country of origin. The country of origin of the corre-
sponding author was recorded and categorized into low
income, lower-middle income, upper-middle income, and
high income economies based on the World Bank Group
classifications [37].
Study Design Characteristics
Study design. The study design for each article was
classified as parallel or cross-over trial. Specific drugs being
compared were recorded.
Comparison group. The comparisons for the primary
outcome were classified as (1) statin versus statin or (2) statin
versus other drug. In statin-versus-statin comparisons, the
‘‘test’’ drug was defined as the newest statin (most recent FDA
approval date) and the older statin as the ‘‘comparator’’ drug.
In statin-versus-other-drug comparisons, the ‘‘test’’ drug was
defined as the statin and the other drug as the ‘‘comparator’’
drug.
Type of primary outcome measure. The primary outcome
measured was classified as (1) surrogate if the end point was a
marker for a clinical event (e.g., lipid levels, artery diameter,
endothelial function) or (2) clinical if a real clinical event (e.g.,
stroke, myocardial infarction, death) was measured.
Sample size.We recorded the number of patients that were
included in the analyses.
Primary results. For each published paper, the result
reported for each primary outcome was categorized as (1)
favorable if the result was statistically significant (p , 0.05 or
confidence interval [CI] excluding no difference) and in the
direction of the test drug being more efficacious or less
harmful (in the case of side effects); (2) inconclusive if the
result did not reach statistical significance; or (3) unfavorable
if the result was statistically significant in the direction of the
comparator drug being more efficacious or less harmful. If a
study explicitly stated that it was designed as a non-inferiority
study and the two comparisons drugs were equivalent, the
result was coded as favorable.
The entire set of results for all primary outcomes in each
paper was then classified as favorable if at least one primary
outcome was favorable and none were unfavorable; other-
wise, the entire set was classified as unfavorable.
Conclusion. The conclusions reported in the published
papers were categorized as (1) favorable if the test drug was
preferred to comparator; (2) about equal if the test drug was
about equal to comparator; or (3) not favorable if the
comparator drug was preferred to the test drug. If a study
explicitly stated that it was designed as a non-inferiority study
and the two drugs being compared were equivalent, the
conclusion was coded as favorable. If an article did not clearly
state that one of the two drugs was better or if the two drugs
had different advantages, the conclusion was coded as ‘‘test
drug about equal to comparator’’. For analysis, conclusions
were categorized as favorable or not favorable (combining
about equal and not favorable).
Funding Information
Funding source. The funding source of each published
study was categorized as (1) industry, (2) private nonprofit, (3)
government, (4) other, (5) multiple sources, (6) no funding,
and (7) none disclosed. For analysis, the funding-source
categories were collapsed into (1) industry, (2) none disclosed/
no funding, and (3) government/private nonprofit.
Financial ties. Data about the financial ties of each author
were extracted and coded for (1) whether or not there were
any financial ties disclosed with the sponsor of the study and
(2) whether or not there were any financial ties disclosed with
any other company (yes, no, or none disclosed).
Role of the sponsor. Information about the role of the
sponsor was coded as (1) role of sponsor not mentioned, (2)
sponsor not involved in study design and analyses, (3) sponsor
involved, or (4) no sponsor involved.
Study Design Characteristics Aimed at Reducing Bias
Studies that met the inclusion criteria were rated for study
design features according to the components reported by
Chalmers et al. [38]. Chalmers used three different categories:
method of treatment assignment (randomization and con-
cealment of allocation), control for whether all participants
enrolled in the trial have been included in the analysis
(intention-to-treat analysis and loss to follow-up), and blind-
ing of participants and investigators. For each category, the
score can range from 0 to 3, where higher scores indicate
better methodological quality. For analysis, we dichotomized
each category into ‘‘adequate’’ (score of 2 or 3) or
‘‘inadequate’’ (score of 0 or 1).
Statistical Analysis
We report the frequency of the different characteristics of
each article. For characteristics where there was sufficient
variability, we analyzed the characteristics by the direction of
results and conclusions to determine whether certain
characteristics were associated with favorable results or
conclusions. Proportions of manuscripts with favorable
results or conclusions were first analyzed using univariate
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logistic regression and estimating odds ratios (ORs) to
identify associations between independent variables and
favorable results and conclusions. Although impact factor
and sample size were continuous variables, they were
modeled categorically because their effects were clearly
nonlinear.
To control for multiple variables simultaneously, we
carried out multivariate logistic regression analysis and
calculated ORs. These models included funding source and
all factors that had p , 0.05 in univariate models for either
favorable results or conclusions. For our primary analysis, we
conducted the regression analyses on our full sample (n ¼
192). For our a priori analysis of drug industry–sponsored
studies, we conducted the regression analyses on the
subsample of studies that were industry funded (n ¼ 95) in
order to examine the association between funding from the
test drug company and results or conclusions that favor the
test drug.
Our target sample size was to have 40 trials that had results
or conclusions favoring the test drug. We chose this sample
size so there would be at least ten trials with favorable results
or conclusions per predictor in a multivariate analysis with
up to four simultaneous predictors. We achieved this target
sample size for both the full sample and subsample of
industry-funded trials. Data were analyzed with SAS software
(version 9.1, SAS Institute, Cary, North Carolina, United
States).
Results
Characteristics of Included Studies
Our final sample consisted of 192 published RCTs (see
Figure 1). The characteristics of the full sample are shown in
Table 1, and the full list of references to included studies is
presented in Table S1. Almost all (98%, 189/192) studies
reported only surrogate outcome measures. There was also
little variability in the peer-review status, study design, or
country of origin or institutional affiliation of corresponding
authors. Therefore, these variables were not included in our
regression analyses. Impact factor and sample size were
divided into quartiles with the upper three quartiles
compared with the lowest quartile. Forty-nine percent of
articles had conclusions that favored the test drug, 15% had a
conclusion that favored the comparator drug, and 36%
concluded that the two drugs were about equal. Of the 192
Figure 1. Flowchart of Manuscript Selection
doi:10.1371/journal.pmed.0040184.g001
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included trials, 95 (49%) disclosed funding from industry
sponsors.
Among the 95 articles declaring industry funding, the role
of the sponsor was disclosed in 20 (21%) of these. One trial
stated that the sponsor was not involved in the study design
and analyses, and 19 trials stated that the sponsor was
involved by providing the study drug, data analyses, or
writing and preparation of the manuscript.
Analysis of Full Sample
Table 2 shows the results of univariate logistic regression
analyses. Studies with adequate blinding were substantially
less likely to report results favoring the test drug than studies
that did not include adequate blinding. Trials with larger
sample sizes were more likely to report conclusions that
favored the test drug, while trials with no disclosed funding
sources were less likely to have conclusions favoring the test
drug compared to trials with industry funding. In multi-
variate analyses, trials with adequate blinding remained
significantly less likely to report statistically significant results
favoring the test drug, and sample size remained associated
with favorable conclusions when controlling for other factors
(Table 3). Pooling non-industry-funded studies and those with
no funding disclosure produced ORs of 1.49 (95% CI 0.75–
3.0, p¼ 0.26) for results and 0.73 (95% CI 0.36–1.46, p¼ 0.37)
for conclusions versus industry-funded studies. Adding
interaction terms for industry funding versus all others with
sample size quartile did not produce a statistically significant
improvement in the fit to the data for results (p ¼ 0.21 by
likelihood ratio test) and also did not show a consistent
pattern (OR of all others 2.1, 1.15, 3.3, 0.42 in first to fourth
sample size quartiles, respectively). For conclusions, the
interaction terms also did not reach statistical significance
overall (p¼0.11), but the pattern was in a consistent direction
(OR of all others 2.2, 1.02, 0.52, 0.18 in first to fourth sample
size quartiles, respectively).
We also conducted a multivariate analysis for the subset of
articles that were statin–statin comparisons (n¼ 112), and the
results were essentially the same as for the comparisons
between statin and any non-statin or statin drug. Trials with
adequate blinding remained significantly less likely to report
statistically significant results favoring the test drug (OR ¼
0.28 [95% CI 0.11–0.73], p¼0.0095), and sample size remained
associated with favorable conclusions (OR ¼ 8.49 [95% CI
1.93–37.36], p ¼ 0.0047) when controlling for other factors.
Table 1. Characteristics of Included Articles by Funding Source (n ¼ 192)
Characteristic Category Total,
n ¼ 192
Funding Source, n (%)
Industrya,
n ¼ 95
Government/Private
Nonprofit, n ¼ 23
No Disclosure/
No Funding,
n ¼ 74
Peer reviewed 192 (100) 95 (100) 23 (100) 74 (100)
Study design Parallel trial 149 (78) 78 (82) 17 (74) 56 (76)
Cross-over trial 43 (22) 17 (18) 5 (26) 18 (24)
Type of primary outcome Surrogate 189 (98) 93 (98) 23 (100) 73 (99)
Clinical 3 (2) 2 (2) 0 1 (1)
Impact factor, quartilesb 0.21–1.76 46 (25) 17 (19) 4 (17) 25 (35)
1.78–3.13 44 (24) 20 (22) 6 (26) 18 (25)
3.14–3.75 47 (25) 32 (35) 4 (17) 11 (16)
3.80–38.57 48 (26) 22 (24) 9 (39) 17 (24)
Comparison Statin versus statin 112 (58) 63 (66) 10 (43) 39 (53)
Statin versus other drug 80 (42) 32 (34) 13 (57) 35 (47)
Sample size, quartiles 7–35 49 (26) 15 (16) 10 (44) 24 (32)
36–92 47 (24) 17 (18) 6 (26) 24 (32)
93–272 48 (25) 24 (25) 6 (26) 18 (24)
287-4162 48 (25) 39 (53) 1 (4) 8 (12)
Primary outcome Favorable to test drug 94 (49) 46 (48) 10 (43) 38 (51)
Not favorable to test drug 98 (51) 49 (52) 13 (57) 36 (49)
Conclusions Favors test drug 94 (49) 54 (57) 10 (43) 29 (39)
Favors comparator drug 28 (15) 16 (17) 3 (13) 10 (14)
Equal 70 (36) 25 (26) 10 (43) 35 (47)
Author from high-income country 174 (91) 91 (96) 20 (87) 63 (85)
Corresponding author’s institution Academic 136 (71) 67 (71) 17 (74) 52 (70)
Private nonprofit 17 (9) 12 (13) 2 (9) 3 (4)
Government 16 (8) 4 (4) 3 (13) 9 (12)
Hospital 15 (8) 7 (7) 1 (4) 8 (11)
Industry 6 (3) 4 (4) 0 2 (3)
Cannot determine 1 (0.5) 1 (1) 0 0
Quality assessment Adequate concealment of allocation 41 (21) 19 (20) 5 (22) 16 (22)
Adequate inclusion in analysis of
all subjects enrolled
46 (24) 31 (33) 7 (30) 9 (12)
Adequate blinding 89 (46) 53 (56) 5 (22) 31 (42)
aIncludes three articles that were sponsored by two companies.
bMedian (range) for impact factor¼ 3.14 (0–39). Data from seven articles were excluded because they were published in journals that had no impact factor, thus the numbers differed for
industry (n ¼ 91) and no disclosure/no funding (n¼ 71).
doi:10.1371/journal.pmed.0040184.t001
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The data used in the analyses are presented in Tables S2
and S3.
Analysis of Industry-Sponsored Trials
In univariate logistic regression analyses of the industry-
sponsored trials, higher impact factor, larger sample size, and
funding from the test drug company were associated with
favorable results, while trials with adequate blinding were less
likely to report statistically significant results favoring the test
drug (Table 4). Larger sample size and funding from the test
drug company were also associated with favorable conclu-
sions (Table 4). In multivariate logistic regression analysis,
funding from the test drug company remained associated
with statistically significant results favoring the test drug (OR
¼ 20.16 [95% CI 4.37–92.98], p , 0.001) or conclusions
favoring the test drug (OR ¼ 34.55 [95% CI 7.09–168.4], p ,
0.001) (Table 5) when controlling for other factors. Studies
with adequate blinding remained less likely to report
statistically significant results favoring the test drug (Table
5). Adding interaction terms for funding by test drug
company with sample size quartile did not produce a
statistically significant improvement in the fit to the data
for results (p ¼ 0.38), although the ORs associated with test
drug company funding did show an increasing pattern (3.8,
8.1, infinite, 59.5 in the first to fourth sample size quartiles,
respectively). For conclusions, the interaction p-value was p¼
0.066, with ORs associated with test drug company funding of
infinite, 2.1, infinite, and 143.2 in the first to fourth sample
size quartiles, respectively. The infinite estimated ORs result
from no favorable outcomes for some combinations of
funding and sample size quartile, making these results
difficult to interpret.
We also conducted the multivariate logistic regression
analysis for the subset of industry-funded studies that were
statin–statin comparisons (n ¼ 63), and the results were
essentially the same as for the comparisons between statin
and any non-statin or statin drug. Funding from the test drug
company remained associated with statistically significant
results favoring the test drug (OR ¼ 16.06 [95% CI 2.22–
116.3], p¼ 0.043) or conclusions favoring the test drug (OR¼
77.09 [95% CI 7.92–749.9], p , 0.001) when controlling for
other factors.
Discussion
We examined the association between study design
characteristics and the results and conclusions of RCTs of
head-to-head comparisons of statins with other drugs. We
hypothesized that the results and conclusions of published
trials would be more likely to favor the statin made by the
sponsor of the study and that other design features, such as
concealment of allocation, blinding, and sample size, would
also be associated with results or conclusions that favor the
statin. We found that the main factor associated with the
results and conclusions of industry-sponsored research to
compare statin drugs with statin or non-statin drugs is
research sponsorship. Our study adds new information to the
body of literature showing that pharmaceutical industry–
sponsored studies comparing drug and placebo are more
likely to favor the drug [14,21–23,25,27,28,39]. Our finding
suggests that favorable results and outcomes are associated
with the specific sponsor of a study, even when all the studies
are industry funded. This finding may help explain why well-
designed head-to-head comparisons of statins and other
drugs sometimes have contradictory results.
There are several possible explanations for our finding of
the strong association between funding source and outcomes
that are favorable to the drug company sponsor. First, it is
possible that pharmaceutical companies selectively fund trials
on drugs that are likely to produce a statistically significant
Table 2. Association between Characteristics of Articles (n¼192) and Statistically Significant Results or Conclusions that Favor the Test
Drug: Univariate Logistic Regression
Characteristic Category Results Favor Test Drug Conclusions Favor Test Drug
Favorable n/
Total n (%)
OR (95% CI) p-Value Favorable n/
Total n (%)
OR (95% CI) p-Value
Impact factor Quartile 1(0.21–1.76) 17/46 (37) 1.00 17/46 (37) 1.00
Quartile 2 (1.78–3.13) 21/44 (48) 1.56 (0.67–3.6) 0.30 21/44 (48) 1.56 (0.67–3.6) 0.30
Quartile 3 (3.14–3.75) 28/47 (60) 2.5 (1.09–5.8) 0.03 26/47 (55) 2.1(0.92–4.8) 0.08
Quartile 4 (3.80–38.57) 22/48 (46) 1.44 (0.63–3.3) 0.38 24/48 (50) 1.71 (0.75–3.9) 0.20
Concealment of allocation Not adequate 70/151 (46) 1.00 71/151 (46) 1.00
Adequate 24/41 (58) 1.63 (0.81–3.3) 0.17 23/41 (56) 1.44 (0.72–2.9) 0.30
Inclusion of all in analysis Not adequate 73/146 (50) 1.00 71/146 (49) 1.00
Adequate 21/46 (46) 0.84 (0.43–1.63) 0.61 23/46 (50) 1.06 (0.54–2.1) 0.87
Blinding Not adequate 61/103 (59) 1.00 56/103 (54) 1.00
Adequate 33/89 (37) 0.41 (0.23–0.73) 0.002 38/89 (37) 0.63 (0.35–1.11) 0.11
Sample size Quartile 1(7–35) 22/49 (45) 1.00 15/49 (45) 1.00
Quartile 2 (36–92) 22/47 (47) 1.08 (0.48–2.4) 0.85 24/47 (47) 2.4 (1.03–5.5) 0.04
Quartile 3 (93–272) 20/48 (42) 0.88 (0.39–1.96) 0.75 19/48 (42) 1.49 (0.64–3.4) 0.36
Quartile 4 (287-4162) 30/48 (63) 2.1 (0.91–4.6) 0.08 36/48 (63) 6.8 (2.8–16.6) ,0.001
Funding source Industry 46/95 (48) 1.00 55/95 (58) 1.00
PNP/government 10/23 (44) 0.82 (0.33–2.1) 0.67 10/23 (44) 0.56 (0.22–1.40) 0.21
No funding disclosed 38/74 (51) 1.12 (0.61–2.1) 0.71 29/74 (39) 0.47 (0.25–0.87) 0.02
PNP, private nonprofit organization.
doi:10.1371/journal.pmed.0040184.t002
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result. This can be accomplished by selecting nonequivalent
doses of drugs for testing [15–17]. A recent review of 42 RCTs
comparing the low-density lipoprotein–lowering ability of
two or mores statins found that almost all of the trials
compared nonequivalent doses of statins [32]. Second, as we
examined only published studies, publication bias, or the
phenomenon of statistically significant results being pub-
lished more frequently than statistically nonsignificant
results, may explain the association of funding and outcome
[40]. Selective reporting of outcomes can also contribute to
biased results and conclusions [4–6]. In addition, industry
sponsorship may be associated with multiple reporting of
studies with favorable findings, emphasizing the imbalance
towards statistically significant results in the published
literature [18,41,42]. Finally, more than one third of the
studies in our sample had no disclosed sponsorship. It is
possible that industry funders or industry-supported authors
could fail to disclose the sponsorship of a published study if
the findings do not support the sponsor’s product. This,
however, would have to be very prevalent to explain by itself
the results in Tables 4 and 5 concerning sponsorship. For
example, nearly all the 29 studies with favorable conclusions
and undisclosed funding would have to be actually funded by
the comparator drug company, and nearly all the 45 studies
without favorable conclusions would have to be funded by the
test drug company in order to erase the difference shown in
Table 4.
We identified a number of weaknesses common to
published statin versus statin or non-statin drug comparisons
that bring into question their clinical relevance. The most
important weakness was the lack of patient-related clinical-
outcome measures. Looking at the totality of available
evidence, we found that almost all studies (98%, 189/192)
used only surrogate outcome measures. Inadequate blinding,
lack of concealment of allocation, poor follow-up, and lack of
intention-to-treat analyses were common among these
studies. These weaknesses suggest that these types of studies
should be used with great caution by those making regulatory
and purchasing decisions.
We found that adequate double blinding was an influential
design feature in our sample. Adequately blinded studies
were less likely to report results favoring the sponsor’s
product. Although RCTs of poorer quality are more likely to
reach biased conclusions [10,43,44], the unreliability of
quality scores has led to the recommendation that trial
quality be assessed for individual features that are aimed to
reduce bias, such as concealment of allocation or blinding
[45]. Recent research further suggests that specific study
design characteristics are not reliably associated with treat-
ment effect sizes across different studies and medical areas
[46]. Thus, the study design characteristics associated with
statistically significant results might vary with the type of
research being examined. We used three items from the
Chalmers et al. [38] methodological quality assessment scale
to assess study design features that might be associated with
results and conclusions. These items focus on important
aspects of trial design: (1) concealment of allocation, (2)
control for whether all patients enrolled in the trial were
included in the analysis (drop outs and intention-to-treat
analyses), and (3) blinding of participants and investigators.
Previous studies showed that these specific characteristics are
associated with bias in clinical trials [10,47,48]. For example,
Schulz and colleagues found that estimates of treatment
effects were exaggerated by 41% for inadequately concealed
trials and by 17% for trials with inadequate double blinding
[10].
Finally, journal characteristics may influence the results
and conclusions of articles as the quality of the reporting may
vary with the journal. For example, articles published in peer-
reviewed journals have superior quality compared to articles
published in non-peer-reviewed journals [15,27]. In our
sample, we had no variability in peer-review status, but we
did observe a small possible association between journal
impact factors and results and conclusions that favored the
test drug.
Our study has several limitations, including our ability to
identify funding sources and financial ties. We categorized
studies as industry funded or not based on each article’s
disclosure of a trial’s funding source(s). Krimsky showed,
however, that there is a lack of disclosure of industry research
support and personal financial ties across a wide variety of
journals [49,50]. Thus, we may be underestimating the
Table 3. Association between Characteristics of Manuscripts (n¼ 192) and Results or Conclusions that Favor Test Drug: Multivariate
Analysis
Characteristic Category Results Favor Test Drug Conclusions Favor Test Drug
OR (95% CI) p-Value OR (95% CI) p-Value
Impact factor (quartiles) Q2 (1.78–3.13) versus Q1 (0.21–1.760 1.28 (0.51–3.19) 0.60 0.89 (0.35–2.27) 0.81
Q3 (3.14–3.75) versus Q1 2.07 (0.82–5.25) 0.12 1.13 (0.43–2.95) 0.80
Q4 (3.80–38.6) versus Q1 1.45 (0.61–3.45) 0.41 1.45 (0.60–3.50) 0.41
Adequate blinding versus inadequate blinding 0.45 (0.23–0.85) 0.01 0.53 (0.27–1.04) 0.06
Sample size (quartiles) Q2 (36–92) versus Q1 (7–35) 1.06 (0.44–2.54) 0.90 2.36 (0.96–5.77) 0.06
Q3 (93–272) versus Q1 0.82 (0.34–1.94) 0.65 1.40 (0.58–3.40) 0.46
Q4 (287-4162) versus Q1 2.57 (0.99–6.66) 0.05 7.55 (2.73–20.86) ,0.001
Funding source PNP/government funding versus
industry funding
1.03 (0.36–2.91) 0.96 0.87 (0.31–2.45) 0.79
No disclosed funding versus
industry funding
1.66 (0.80–3.44) 0.17 0.69 (0.33–1.44) 0.32
PNP, private nonprofit organization.
doi:10.1371/journal.pmed.0040184.t003
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number of industry-sponsored studies and personal financial
ties of investigators.
The market for statins is competitive. The National
Cholesterol Education Program update of the Adult Treat-
ment Panel III guidelines expanded both the scope and
intensity of low-density lipoprotein–lowering therapy for
prevention of cardiovascular disease [51]. To achieve the
goals in the guideline, millions of Americans would need to
be placed on cholesterol-lowering medication in higher doses
and for a longer period, thereby increasing the number of
prescriptions for statin drugs [51,52]. Eight of the nine
members of the National Cholesterol Education Program
panel had financial ties with pharmaceutical companies that
manufactured statin drugs [51,52]. Our findings suggest that
available data on choosing between statins based on head-to-
head comparisons may also be influenced by financial
conflicts of interest. Our findings may be generalizable to
other classes of drugs with competitive markets.
There is increasing concern that the funding source
influences outcomes and conclusions of medical research
[3]. At the same time, industry support of biomedical research
has increased dramatically during the past few decades
[53,54]. The growing proportion of industry-funded studies
could shift the balance of published trials more towards
studies that favor new drugs [55]. This trend and our finding
that, for one class of drugs, the results and conclusions of
trials tend to favor the drug that is made by the sponsor raises
important considerations for selecting drugs within a class.
Sponsorship bias, even when controlling for other confound-
ing study characteristics, may be the main explanation for
Table 4. Association between Characteristics of Industry-Funded Articles (n¼ 95) and Statistically Significant Results and Conclusions
that Favor the Test Drug: Univariate Logistic Regression
Characteristic Category Results Favor Test Drug Conclusions Favor Test Drug
Favorable n/Total n (%) OR (95% CI) p-Value Favorable n/Total n (%) OR (95% CI) p-Value
Impact factor Quartile 1 (0.21–1.76) 4/17 (24) 1.00 7/17 (41) 1.00
Quartile 2 (1.78–3.13) 8/20 (40) 2.17 (0.52–9.09) 0.29 11/20 (55) 1.75 (0.47–6.45) 0.40
Quartile 3 (3.14–3.75) 19/32 (59) 4.8 (1.26–17.9) 0.02 19/32 (59) 2.1 (0.63–6.9) 0.23
Quartile 4 (3.80–38.6) 11/22 (50) 3.25 (0.80–13.2) 0.10 14/22 (64) 2.5 (0.68–9.2) 0.17
Concealment of
allocation
Not adequate 33/75 (44) 1.00 41/75 (55) 1.00
Adequate 13/20 (65) 2.36 (0.85–6.59) 0.10 14/20 (70) 1.93 (0.67–5.6) 0.22
Inclusion of all in
analysis
Not adequate 32/65 (49) 1.00 37/65 (49) 1.00
Adequate 14/30 (47) 0.90 (0.38–2.15) 0.82 18/30 (60) 1.14 (0.47–2.7) 0.78
Blinding Not adequate 27/42 (64) 1.00 28/42 (67) 1.00
Adequate 19/53 (36) 0.31 (0.13–0.72) 0.007 27/53 (51) 0.52 (0.22–1.20) 0.13
Sample size Quartile 1 (7–35) 5/15 (33) 1.00 3/15 (20) 1.00
Quartile 2 (36–92) 8/17 (47) 1.78 (0.42–7.5) 0.43 9/17 (53) 4.5 (0.92–21.9) 0.06
Quartile 3 (93–272) 7/24 (29) 0.82 (0.21–3.3) 0.78 11/24 (46) 3.4 (0.76–15.1) 0.78
Quartile 4 (287-4162) 26/39 (67) 4.0 (1.13–14.2) 0.03 32/39 (82) 18.3 (4.05–82.5) ,0.001
Funding source Comparator drug 3/30 (10) 1.00 4/30 (13) 1.00
Test drug 43/65 (66) 17.6 (4.8–64.5) ,0.001 51/65 (79) 23.7 (7.08–79.2) ,0.001
Author financial ties Tie with sponsor 25/47 (53) 1.00 29/47 (62) 1.00
No tie with sponsor 21/48 (44) 0.68 (0.30–1.54) 0.36 26/48 (54) 0.73 (0.32–1.66) 0.46
doi:10.1371/journal.pmed.0040184.t004
Table 5. Association between Characteristics of Industry-Funded Manuscripts (n¼95) and Results or Conclusions that Favor Test Drug:
Multivariate Analysis
Characteristic Category Results Favor Test Drug Conclusions Favor Test Drug
OR (95% CI) p-Value OR (95% CI) p-Value
Impact factor Q2 (1.78–3.13) versus Q1 (0.21–1.76) 1.07 (0.17–6.88) 0.94 1.26 (0.16–10.09) 0.83
Q3 (3.14–3.75) versus Q1 2.69 (0.51–14.16) 0.24 0.73 (0.12–4.50) 0.73
Q4 (3.80–38.6) versus Q1 1.97 (0.35–10.93) 0.44 2.37 (0.36–15.54) 0.37
Adequate blinding versus inadequate blinding 0.27 (0.08–0.89) 0.03 0.29 (0.07–1.21) 0.09
Sample size Q2 (36–92) versus Q1 (7–35) 2.02 (0.29–14.23) 0.48 7.50 (0.80–70.42) 0.08
Q3 (93–272) versus Q1 0.63 (0.10–3.92) 0.63 7.01 (0.86–56.98) 0.07
Q4 (287-4162) versus Q1 4.40 (0.84–23.01) 0.08 63.29 (6.65–602.4) ,0.001
Funded by test drug company versus comparator
drug company
20.16 (4.37–92.98) ,0.001 34.55 (7.09–168.4) ,0.001
doi:10.1371/journal.pmed.0040184.t005
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contradictory findings of drug–drug comparison trials. This
bias in drug–drug comparison trials should be considered
when making health-policy decisions regarding drug choice,
such as drug formulary decisions. Reviewers of published
reports that disclose funding by the makers of the product
being tested should be more critical of the methods than if
the reports are not industry sponsored [56]
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Editors’ Summary
Background. Randomized controlled trials are generally considered to
be the most reliable type of experimental study for evaluating the
effectiveness of different treatments. Randomization involves the
assignment of participants in the trial to different treatment groups by
the play of chance. Properly done, this procedure means that the
different groups are comparable at outset, reducing the chance that
outside factors could be responsible for treatment effects seen in the
trial. When done properly, randomization also ensures that the clinicians
recruiting participants into the trial cannot know the treatment group to
which a patient will end up being assigned. However, despite these
advantages, a large number of factors can still result in bias creeping in.
Bias comes about when the findings of research appear to differ in some
systematic way from the true result. Other research studies have
suggested that funding is a source of bias; studies sponsored by drug
companies seem to more often favor the sponsor’s drug than trials not
sponsored by drug companies
Why Was This Study Done? The researchers wanted to more precisely
understand the impact of different possible sources of bias in the findings
of randomized controlled trials. In particular, they wanted to study the
outcomes of ‘‘head-to-head’’ drug comparison studies for one particular
class of drugs, the statins. Drugs in this class are commonly prescribed to
reduce the levels of cholesterol in blood amongst people who are at risk
of heart and other types of disease. This drug class is a good example for
studying the role of bias in drug–drug comparison trials, because these
trials are extensively used in decision making by health-policy makers.
What Did the Researchers Do and Find? This research study was based
on searching PubMed, a biomedical literature database, with the aim of
finding all randomized controlled trials of statins carried out between
January 1999 and May 2005 (reference lists also were searched). Only
trials which compared one statin to another statin or one statin to
another type of drug were included. The researchers extracted the
following information from each article: the study’s source of funding,
aspects of study design, the overall results, and the authors’ conclusions.
The results were categorized to show whether the findings were
favorable to the test drug (the newer statin), inconclusive, or not
favorable to the test drug. Aspects of each study’s design were also
categorized in relation to various features, such as how well the
randomization was done (in particular, the degree to which the processes
used would have prevented physicians from knowing which treatment a
patient was likely to receive on enrollment); whether all participants
enrolled in the trial were eventually analyzed; and whether investigators
or participants knew what treatment an individual was receiving.
One hundred and ninety-two trials were included in this study, and of
these, 95 declared drug company funding; 23 declared government or
other nonprofit funding while 74 did not declare funding or were not
funded. Trials that were properly blinded (where participants and
investigators did not know what treatment an individual received) were
less likely to have conclusions favoring the test drug. However, large
trials were more likely to favor the test drug than smaller trials. When
looking specifically at the trials funded by drug companies, the
researchers found various factors that predicted whether a result or
conclusion favored the test drug. These included the impact of the
journal publishing the results; the size of the trial; and whether funding
came from the maker of the test drug. However, properly blinded trials
were less likely to produce results favoring the test drug. Even once all
other factors were accounted for, the funding source for the study was
still linked with results and conclusions that favored the maker of the test
drug.
What Do These Findings Mean? This study shows that the type of
sponsorship available for randomized controlled trials of statins was
strongly linked to the results and conclusions of those studies, even
when other factors were taken into account. However, it is not clear from
this study why sponsorship has such a strong link to the overall findings.
There are many possible reasons why this might be. Some people have
suggested that drug companies may deliberately choose lower dosages
for the comparison drug when they carry out ‘‘head-to-head’’ trials; this
tactic is likely to result in the company’s product doing better in the trial.
Others have suggested that trials which produce unfavorable results are
not published, or that unfavorable outcomes are suppressed. Whatever
the reasons for these findings, the implications are important, and
suggest that the evidence base relating to statins may be substantially
biased.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040184.
 The James Lind Library has been created to help people understand
fair tests of treatments in health care by illustrating how fair tests have
developed over the centuries
 The International Committee of Medical Journal Editors has provided
guidance regarding sponsorship, authorship, and accountability
 The CONSORT statement is a research tool that provides an evidence-
based approach for reporting the results of randomized controlled
trials
 Good Publication Practice guidelines provide standards for responsible
publication of research sponsored by pharmaceutical companies
 Information from Wikipedia on Statins. Wikipedia is an internet
encyclopedia anyone can edit
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